Does low-grade inflammation increase omega-3 demand?

Systemic low-grade inflammation fundamentally alters lipid metabolism, transforming eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) from structural membrane components into active therapeutic substrates.

Mechanistic pathways of SPM biosynthesis

• During inflammatory signaling, membrane-bound EPA and DHA are liberated and enzymatically converted into specialized pro-resolving mediators (SPMs), including resolvins, protectins, and maresins.
• This biosynthetic pathway is mediated by cyclooxygenase (COX, including COX-2) and lipoxygenase (LOX) enzymes, which orchestrate the transition from active inflammation to resolution.
• Once synthesized, these SPMs act as highly localized agonists that limit neutrophil recruitment, promote macrophage efferocytosis (the clearance of cellular debris), and downregulate pro-inflammatory cytokine production to restore tissue homeostasis.

Elevated substrate turnover and omega-3 demand

• Because SPM biosynthesis is an active, ongoing process during chronic low-grade inflammation, it drives a continuous, accelerated clearance and turnover of EPA and DHA.
• This constant metabolic utilization depletes membrane-bound fatty acid stores, raising the baseline functional requirement for omega-3 fatty acids.
• If intake of EPA and DHA is insufficient to compensate for this accelerated consumption, the depletion of these precursor pools can impair adequate SPM synthesis, potentially perpetuating unresolved, chronic inflammatory states.

Bottom line

• Chronic low-grade inflammation accelerates the enzymatic conversion of EPA and DHA into specialized pro-resolving mediators, significantly increasing overall omega-3 demand to sustain active inflammatory resolution and prevent tissue depletion.